Short Communication Volume 3 Issue 2
Consultant, King Faisal Specialist Hospital and Research Centre Jeddah, Saudi Arabia
Correspondence: Salman Shahid, Consultant King Faisal Specialist Hospital and Research Centre Jeddah, Ex Clinical Lead Diabetes Sandwell and Birmingham CCG NHS, UK MBBS MRCP MRCGP FRCGP MSc Health Sciences, Diabetes Mellitus, GPwSI Diabetes, Saudi Arabia
Received: December 04, 2014 | Published: July 29, 2016
Citation: Shahid S. Integrated diabetes care, brining specialist diabetes care to primary care-diabetes local improvement scheme SWBCCG. Endocrinol Metab Int J. 2016;3(2):41-43. DOI: 10.15406/emij.2016.03.00045
IDF, international diabetes federation; QOF, quality and outcomes framework;IFG, impaired fasting glucose; IGT, impaired glucose tolerance; WHO, world health organization; CCG, clinical commissioning group; DiCE, diabetes community care extension; LIS, local improvement scheme
Diabetes is a chronic disease characterised by an inability to regulate blood glucose concentrations. According to latest figures from International Diabetes federation1 worldwide prevalence of Diabetes is 8.3%. There are 387 million people worldwide with Diabetes, and it is estimated that by 2035 there will be an additional 205 million people diagnosed with diabetes in the world.1 It is also estimated that there are more than 3 million people in the world who have undiagnosed Diabetes. In United Kingdom there are 3.2 million people who have been diagnosed with diabetes in the UK.2
In 2013 in England, the number of people aged 16 and older with diabetes was approximately 2.7 million, accounting for 6.0% of England’s population. Figures based on AHPO diabetes prevalence model estimates that by 2025, there will be approximately 5 million people with diabetes in the UK3 it is estimated to rise to 4.6 million-that is, nearly 10% of the population-by 2030. Around 90% of these people will have type 2 diabetes. An estimated 850,000 people in England may have diabetes but have not been diagnosed.4 Around 1 in 7 adults may have either impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), based on World Health Organization (WHO) criteria.4
Diabetes can lead to serious complications in the long term. It is the most common cause of visual impairment and blindness among people of working age. It is also the most common cause of kidney failure and non-traumatic lower limb amputations. People with diabetes are up to five times more likely to have cardiovascular disease and stroke, compared to those without diabetes4 In England, people aged between 20 and 79 with type 2 diabetes are 1.6 times as likely to die prematurely than those without the disease (The Healthcare Quality Improvement Partnership 2011). It is estimated that, generally, they die 10 years earlier than average.4 Treating type 2 diabetes and its complications currently costs the NHS £8.8 billion a year5 just over 8% of its annual budget. The cost of prescribing drugs to treat diabetes rose from £513.9 million in 2005/06 to £725.1 million in 2010/11 (The NHS Information Centre for Health and Social Care 2011). The indirect costs associated with type 2 diabetes, such as those related to an increase in premature deaths and illness, loss of productivity and the need for informal care, are estimated at £13 billion.5 By 2035/36, the cost of direct care and other indirect costs for type 2 diabetes are estimated to rise to £15.1 billion and £20.5 billion respectively.5
The growing burden of type 2 diabetes is due to obesity, sedentary lifestyles, dietary trends and an ageing population (Yorkshire and Humber Public Health Observatory 2010). However, lifestyle interventions targeting these risk factors have reduced its incidence by about 50% among high risk individuals.6
Author, Dr Salman Shahid, worked as Clinical Lead for Diabetes in Sandwell and West Birmingham Clinical Commissioning Group (CCG). In this CCG the prevalence of diagnosed diabetes among people aged 17 years and older is 7.9% compared to 6.1% in similar CCGs. In 2011/12 there were 32, 533 people aged 17 years and older diagnosed with diabetes. In 2011/12, only 65.7% of adults with diabetes had a HbA1c measurement of 59mmol/mol or less. This is higher than in other similar CCGs and lower than England. Risk factors for type 2 diabetes are increasing within Sandwell and West Birmingham’s population. We have increasing numbers in the older at risk age groups; the ethnic groups that are at increased risk are growing in number and are ageing and obesity is increasing. Diabetes is more prevalent in Sandwell and West Birmingham compared with the national and regional average.
People with diabetes in Sandwell PCT were 39% more likely to have a myocardial infraction, 17.8% more likely to have a stroke, 45.1% more likely to have a hospital admission related to heart failure and 19.2% more likely to die than the general population in the same area.7 In view of these observed disparities in terms of higher prevalence and poor outcomes, Sandwell and West Birmingham CCG embarked on a Local Improvement Scheme for Diabetes (SWB CCG Diabetes LIS, 2014). Main aims and objectives of this improvement scheme were:
Sandwell and West Birmingham CCG comprised of more than 113 GP practices, representing a wide and diverse experience in management of Diabetes. In View of this diversity of experience and prior skills, SWBCCG’s Diabetes Local improvement Scheme (LIS) was launched with two levels of Tiers.
Tier 1-practices for enhanced diabetes care
Tier 1 practice were responsible for providing diabetes management for adults of its type 2 and stable type 1 patients at a practice level with the support of a specific named Diabetes Community Care Extension (DiCE) team (Diabetes Consultant and Diabetes Specialist Nurse). The aim was to reach a point where 95% of the care for type 2 and stable type 1 diabetics occurs within the practice without the need for onward referral.
Each practice signed up to the LIS will have named DiCE Team. As they begin working together, the detail and type of support tier 1 practice and patients require was to be readily established. Some of the examples of the support DiCE teams offer included:
Tier 2-injectable therapies initiation and ongoing management
Practices opting to choose this level were responsible for provided in accordance with NICE Clinical Guidelines, NICE Technology Appraisals, locally agreed pathways and Health Economy Formulary with responsibility sitting with the prescribing clinician. Patients discharged from the Specialist Diabetes Service were to receive all ongoing diabetes care from the practice in accordance with the locally agreed pathways. The practice was responsible for communicating with the patient and liaising with the Specialist diabetes team to ensure a smooth and appropriate transition of care. The ongoing management of patients on injectable therapies was planned to be in line with locally agreed pathways. Local pathways and guidelines for use of pharmacological agents (Oral and injectable) in management of diabetes were developed and incorporated in this LIS.
Accreditation of practices
In order to participate in level 1 of the Diabetes Local Incentive Scheme providers must have met the following requirements:
In order to participate in level 2 of the Diabetes Local Incentive Scheme providers were required to be delivering level 1 enhanced diabetes care and in addition to the accreditation requirements of level 1 all GPs and Practice Nurses were required to:
Financial Incentives for the practices
Tier 1 Practices qualified for £15 per registered diabetic patient in one payment at the start of the financial year. Whereas Tier 2 practices with in house injectable therapy initiation qualified for £100 for GLP1 analogue initiation and £200 for an Insulin initiation subject to strict adherence to NICE criteria for initiation of these therapies.
Participating Practice’s agreed to be monitored against the following indicators:
This Diabetes Local Improvement Scheme (LIS) has now been successfully in operation for the last 18 months approximately. This model of Diabetes care delivery has been widely popular and taken up by the local practices.
None.
The author declares that there are no conflicts of interest.
©2016 Shahid. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.